Smokemonster
6 years ago
Didn’t see this posted here, so thought I would.
Beleave Announces Initial Cannabis Oil Sales After Receiving Health Canada Authorization Derivatives with Higher-Margins Increasing Growth and Revenues
Toronto, Ontario— April 8, 2019 – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp has commenced sales of cannabis oil products at its licensed facility in Hamilton, Ontario.
Beleave has completed its first wholesale transfer of two bulk lots of cannabis oil to another standard processor license holder, as well as having begun cannabis oil product sales to medicinal patients through its online store https://shop.beleave.com. The Company received authorization from Health Canada to sell cannabis oil products in January 2019.
“We've been looking forward to sharing these efforts with our patients and the entire Beleave community. I'm happy to say that the time has finally come,” said Roger Ferreira, Chief Science Officer at Beleave. “Our whole team has been working hard to ensure we're delivering on our commitment to produce high-quality products that we can all be proud of. We continue to invest in our research and development pipeline in anticipation of future opportunities in the Canadian cannabis derivatives market.”
Current product offerings available to medicinal patients include a blended and balanced THC/CBD cannabis oil. These high-quality and pure cannabis oil products are being offered to patients in convenient and easy-to-use 30 mL bottles with an applicator – allowing for precise dosing control by the patient. MCT, a non-allergenic, flavourless and odourless oil widely-used for pharmaceutical applications, will be used as the carrier oil for Beleave's cannabis oil products to assist in the timely delivery and absorption of THC and CBD.
Cannabis oil production is already underway at Beleave's industrial extraction laboratory using proprietary (patent-pending) methods. This process involves the activation, extraction and purification of THC and CBD using only potable components, without using any organic solvents. In addition to producing oils for Beleave's own medicinal patients, the Company is actively engaged in contract negotiations to offer the same extraction, processing, packaging and distribution services to other micro and standard processor licensed companies.
“We are very excited and proud of our scientific research team and the quality of the work they're producing,” said Bill Panagiotakopoulos, Chief Executive Officer at Beleave. “In conjunction with our dried flower products, we feel our company's success will also rely on the production and processing of oils and derivatives for the adult recreational market, antici- pated for later this year. This is another great milestone for Beleave.”
Patent applications submitted for the Company's processes include a regularly submitted United States patent application (U.S. Patent Application 16/201,547), as well as a Patent Cooperation Treaty (PCT) and International Application (PCT Patent Application PCT/- CA2018/051508).
Nelly 15
6 years ago
Kevin Keagan Joins Beleave as Chief Communications Officer
TORONTO, Oct. 24, 2018 /CNW/ - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is
pleased to announce that Kevin Keagan has joined the Company as Chief Communications Officer, and a member of
the Executive Team.
Mr. Keagan brings his extensive experience, with over 25 years in capital markets, working within the financial services
industry to provide oversight to the operation, expansion, and direction of Beleave's communications and capital
markets initiatives. As the Company prepares for exciting announcements in the next year, Mr. Keagan will provide
valuable strategic guidance to support the Company's growth and development in the burgeoning cannabis industry.
Having spent over 13 years as Head of Equity Trading at two of the largest asset managers in Canada, Mr. Keagan
offers a unique insight to the inner workings of not only the investment decision-making process, but he also developed
a close working relationship with broker dealers and investment managers on a global scale. Mr. Keagan was a
member of the International Trader Forum advisory committee, and was a board member of both the Canadian
Securities Trader Association and Institutional Equity Trader Association. He holds the CIM designation.
"We are thrilled to have Kevin join our team," said Andrew Wnek, Beleave CEO. "He shares our focus on innovation and
market intelligence and has demonstrated remarkable leadership abilities throughout his career."
"I am excited to be joining Beleave at this time of great change and opportunity in the cannabis space," said Keagan. "I
am looking forward to working with the team to further enrich the understanding of our partners, customers, and
stakeholders. Beleave is on the cusp of massively expanding its footprint in the cannabis space and I am delighted to
be a part of this unfolding success story."
Nelly 15
6 years ago
Beleave Signs Agreement to Acquire 250,000 Square Feet of Greenhouse Space and 85 Acres of Land to Expand its Production Capabilities
The new facility purchased from Heritage Garden Gallery.
TORONTO, Sept. 6, 2018 /PRNewswire/ - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce it has finalized plans to acquire 250,000 square feet of greenhouse space and 85 acres of land in London, Ontario to cultivate and harvest cannabis for distribution and sale in Canada.
Located just south of the City of London, the facility will become a contributor to the local economy, both through investments and job creation. The unique location of the facility provides a number of competitive advantages, including access to abundant hydro power, low-cost natural gas, and close proximity to major highways providing quick and easy access for employees, shipping, and receiving.
Beleave purchased the greenhouse space and land for $6,700,000 using a combination of cash ($1,172,500 in cash), Beleave common shares ($1,172,500 in shares) and mortgage financing ($4,355,000 in financing) at 6% annual interest.
The Company has begun the application process for Health Canada approval to cultivate and harvest cannabis and anticipates bringing the existing greenhouse facility online in two phases; Phase 1 providing 100,000 square feet of flowering capacity with Phase 2 coming online shortly thereafter. The remaining land will be designated for the construction of additional greenhouses and the cultivation of outdoor growing spaces, allowing Beleave to continue its above-average yields and maintain its high-grade product as it supplies its existing and growing distribution channels.
"Beleave continues to identify innovative approaches to financing which allow us to maximize the value of our asset base and ensures we maintain our excellent balance sheet," said Beleave CEO, Andrew Wnek. "This acquisition is a critical part of our strategic plan to continue being a leader in the Canadian cannabis industry. This property already houses state-of-the-art greenhouse space that we can immediately put to use once approved by Health Canada, and additional land allowing us to build some of the largest greenhouses in the region."